WHO Launches Urgent Dual-Drug Trial Against Spreading Bundibugyo Ebola in Central Africa

In a critical juncture for global health security, the World Health Organization (WHO) has initiated an urgent clinical trial, deploying a novel dual-drug strategy to combat the escalating outbreak of the Bundibugyo ebolavirus in Central Africa. As this lesser-known but equally virulent strain propels a fast-moving crisis across the region, the launch of this trial next week represents a pivotal moment – a desperate race against time to halt a pathogen that currently lacks targeted therapies and vaccines, threatening to destabilize already fragile health systems and communities. This swift, coordinated response underscores the international community's commitment to preventing another devastating epidemic, marking a significant strategic shift in confronting the diverse and persistent threat of the Ebola family of viruses.